

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder noted that for talquetamab there is a requirement for patients to stay in or near the hospital for 48 hours after each set-up dose. And the costs incurred by hospital visits and time off work will have a more significant impact on people with lower incomes. The stakeholder considered that implementation plans must ensure all patients have the opportunity to access this treatment.

A stakeholder also noted that patients from some ethnic subgroups have worse outcome in myeloma and may therefore more quickly come to need for fourth-line treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Implementation

Implementation of treatment pathways is not an issue that can be addressed by a NICE technology appraisal recommendation.

Differential outcomes

The committee will need to consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

--

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No	

Approved by Associate Director (name): Ross Dent

Date: 13/12/2024